Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466790 · ClinicalTrials.gov registry record · Phase 2
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
A Phase 2 study, sponsored by Janssen R&D Ireland.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT01466790 is a Phase 2 study that has completed, run by Janssen R&D Ireland. The registered enrollment target is 168 participants.
The verdict
NCT01466790, a Phase 2 study, has completed, sponsored by Janssen R&D Ireland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of TMC435 plus PSI-7977 (GS7977) with or without ribavirin in patients who are chronically infected with genotype 1 hepatitis C virus (HCV) and who did not respond to prior peginterferon/ribavirin therapy or are HCV treatment-naive (patients who never received treatment for HCV infection).
Interventions
- DRUG Ribavirin
- DRUG TMC435
- DRUG PSI-7977 (GS7977)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01466790
The ClinicalTrials.gov registry entry for NCT01466790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen R&D Ireland, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01466790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01466790 about?
NCT01466790 is a clinical study titled "A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients". The purpose of this study is to investigate the efficacy and safety of TMC435 plus PSI-7977 (GS7977) with or without ribavirin in patients who are chronically infected with genotype 1 hepatitis C virus (HCV) and who did not respond to prior peginterferon/ribavirin therapy or are HCV treatment-naive ...
What is the current status of trial NCT01466790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2012-01. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01466790?
The interventions under investigation include: Ribavirin (DRUG), TMC435 (DRUG), PSI-7977 (GS7977) (DRUG).
Who is sponsoring clinical trial NCT01466790?
This trial is sponsored by Janssen R&D Ireland, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.